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INTRODUCTION
By definition, immune thrombocytopenia is an acquired 
autoimmune disease characterised by an isolated low 
plate let count number (<100 x 109/L). The disorder is clas-
sified as primary immune thrombocytopenia (ITP) in the 
absence of any obvious initiating and/or underlying cause, 
and as secondary ITP in association with autoimmune 
disorders (systemic lupus erythematosus (SLE), the anti-
phospholipid syndrome (APS), etc.), some immunodefi-
ciency syndromes (common variable immunodeficiency 
syndrome (CVID), adult lymphoproliferative syndrome, 
etc.), lymphoproliferative disorders (chronic lymphocytic 
leukaemia, Hodgkin’s disease, large granular T-lymphocyte 
proliferation, etc.), persistent  infections (human immuno-
deficiency virus (HIV), hepatitis C (hep C) virus or Helico-
bacter (H) pylori) and vaccination.2,3 Several retrospective 
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SUMMARY 
The Belgian Hematology Society (BHS) updated the 2013 guidelines for diagnosis and treatment of primary 
immune thrombocytopenia (ITP).¹ As knowledge about ITP pathophysiology is increasing, the mode of  action 
of old therapies is better understood and novel drugs are introduced to target more specific pathways. 
 Corticosteroids with or without intravenous immunoglobulins (IgIV) remain the first line treatment. According 
to the updated international guidelines, a short course of corticosteroids rather than a prolonged treatment 
has to be recommended. The same guidelines stress that consequent therapies as thrombopoietic agents 
(TPO­RAs) and rituximab should be available independent of duration of ITP. Although the majority of 
 recommendations is based on very low­quality evidence, it is strongly advised to individualise the ITP 
 management taking patient values and preferences in account. The main treatment goal in all ITP patients 
must be to maintain a safe platelet count to prevent or stop bleeding with a minimum of toxicity and not to 
normalise the platelet count.
(BELG J HEMATOL 2020;12(3):112-27)
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analyses confirm that approximately 80% of immune 
thrombocytopenia’s have a primary and 20% a secondary 
origin.4,5 Even today, as no reliable test to diagnose ITP 
exist, ITP remains a diagnosis of exclusion. In one ITP 
register, misdiagnosis was seen in one out of seven sus-
pected primary ITP patients.6 In patients refractory to ≥2 
treatments the percentage of primary ITP goes even down 
to 50% meaning that diagnosis must be strongly recon-
sidered in refractory patients. Myelodysplasia, a bone 
marrow failure syndrome, an inherited thrombocytopenia 
or a secondary ITP are mostly responsible for the throm-
bocytopenia in the other 50% of difficult to treat patients.7 
ITP is further defined as newly diagnosed (duration less 
than three months after diagnosis), persistent (duration 
three to twelve months when spontaneous remission is 
not reached or complete response (CR) to therapy is not 
maintained) and chronic ITP (duration more than twelve 
months).2
INCIDENCE
ITP affects all age groups. Although there are still differ-
ences between paediatric ITP (abrupt onset, more bleeding 
symptoms, higher spontaneous remission rate) and adult 
ITP (more comorbidities, higher risk of intracranial haem-
orrhage, likelihood of chronicity), many similarities are 
found especially between the older children, adolescents 
and young adults.8 Data from the paediatric and adult 
 registry on chronic ITP showed that a platelet count of 
>100 x 109/L was reached in 71% of children and 49% 
of adults twelve months after diagnosis.9 The incidence of 
ITP among men and women differs with age, meaning a 
male predominance below five and above 60 years and 
a female predominance between 6-60 years.10,11  Data on 
epidemiology show an annual incidence of newly diag-
nosed ITP among adults ranging from 2 to 4 per 100,000 
persons per year and a prevalence up to 10 per 100,000 
persons per year.10,12 A recent ITP report from US clinical 
practice showed an even higher annual incidence of 6.1 
per 100,000 persons (all ages).13 However, ITP is still a 
rare disease fulfilling the criteria of an orphan disease 
(prevalence <5/10000). 
PATHOGENESIS (Figure 1)14-17 
New insights in the pathophysiology underlying ITP have 
FIGURE 1. Pathophysiology of ITP and mode of action of current and future treatments.
Abbreviations: B regs: regulatory B cells, BTK: Bruton tyrosine kinase, CD4 T: CD 4 T cell, CD 8 T: CD8 T cell, FcR: Fc receptor, 
FcRn: neonatal Fc receptor, Igs: immunoglobulins, IgIV: intravenous immunoglobulins, Syk: spleen tyrosine kinase, TPO: 
thrombopoitin, TPO-R: thrombopoitin receptor, TPO-RAs: thrombopoitin receptor agonists, T regs: regulatory T cells.
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taught us that not only accelerated peripheral platelet 
destruction but also suppression of the production of 
new platelets can be responsible for the thrombocyto-
penia. Antibody-loaded platelets bind to macrophages and 
dendritic cells by the Fc gamma receptors (FcγRs) and are 
removed, primarily in the spleen. These antibody-loaded 
platelets can also be destroyed by direct complement 
 mediated cell lysis. A recent analysis showed that com-
plement levels are reduced in a one third of patients and 
are associated with severe disease.18 Platelets can also be 
destroyed by CD8 cytotoxic T cells (direct platelet lysis, 
platelet apoptosis due to granzyme B, platelet desialyation 
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TABLE 1. Safe platelet count for medical 
 interventions in patients with platelet production 
problems.23,24*
Dental care ≥ 10-20 x 109/L
Extractions (simple) ≥ 30 x 109/L
Extractions (complex, molar) ≥ 50 x 109/L
Lumbar puncture: elective ≥ 40-50 x 109/L
Lumbar puncture: vital indication ≥ 20 x 109/L
Central venous catheter insertion ≥ 20 x 109/L
GI endoscopy with biopsy ≥ 20 x 109/L
Bronchoscopy ≥ 20 x 109/L 
Bronchoscopy with biopsy ≥ 50 x 109/L
Joint puncture ≥ 20 x 109/L
Organ biopsy ≥ 50 x 109/L 
(<for bone  
marrow biopsy)
Minor surgery ≥ 50 x 109/L
Delivery ≥ 50 x 109/L
Major surgery 
(including neurosurgery)
≥ 80 x 109/L
Epidural anaesthesia ≥ 70 x 109/L
Major neurosurgery ≥ 100 x 109/L
Single antiplatelet or anticoagulant ≥ 30-50 x 109/L
Dual antiplatelet and anticoagulant ≥ 50-70 x 109/L
* these thresholds, adapted from safe platelet counts in patients 
with platelet production problems, are mainly based on  
« expert opinion » rather than « evidence-based data » and 
must be individualized to the patient bleeding history
TABLE 2. Characteristics of treatment with 
 corticosteroids. 
No preference to choose (methyl)prednisolone or 
 dexamethasone (dexamethasone has a longer half-life, 
no mineral corticosteroid effect, a potent anti-plasma cell 
effect and provides a faster platelet response)
(Methyl)prednisolone or equivalent: 
•  continuous treatment for 6-8 weeks
•  Start dose: 1 mg/kg (maximum of 80 mg/d) 
 prednisolone) for 7-14 days
•  Tapering: slow tapering (5-7 weeks) during the 
 following weeks if responsive, rapid tapering  
(in 1 week) if not responsive
Dexamethasone: 40 mg/d for 4 days, to be repeated 
after 15 or 28 days for 1 to 3 cycles, depending on the 
response
Short term response of corticosteroids: ± 80%
Durable response of corticosteroids: 30-50% 
Mode of action: modulates T cells (restoring Th1/
Th2 ratio, T regs) modulates B cell activation (B cells, 
B regs, plasma cells) and modulate DCs which lead 
to  impairment of antibody production, clearance of 
 antibody loaded platelets by phagocytes, increase of 
thrombopoiesis, improvement vascular integrity, etc.
Side effects: changing facial and body features, arterial 
hypertension, myopathy, diabetes mellitus,  psychological 
 problems, osteoporosis, osteonecrosis, cataract, 
 glaucoma, etc.
More side effects compared with other therapies leading 
to dose reduction and treatment discontinuation
Absolute contraindication for steroids: acute viral 
 infection (Herpes simplex or Herpes zoster, etc.),  
hep B s Ag positive, chronic active hepatitis
Relative contraindication for steroids: peptic ulcers, 
bacterial infections, history of tuberculosis,  mycosis, 
parasitosis, uncontrolled hypertension, diabetes 





with hepatic removal). The macrophages after ingesting 
the antibody-loaded platelets act as antigen presenting 
cells and expose platelet epitopes, which stimulate CD4 
helper T cells with a Th1 phenotype, which activate B cells 
to produce platelet specific autoantibodies. This process is 
predominantly taking place in the spleen. During active 
disease, it has been shown that the CD4 cells with a Th1 
phenotype are increased, regulatory T cells responsible for 
self-tolerance decreased and regulatory B cells regulating 
antibody production also reduced.  During ITP remission 
(spontaneous or treatment free-remission (TFR)) CD4 
T cells show a Th2/3 phenotype and regulatory T and 
B cells are restored. Platelet production is frequently 
 reduced because autoantibodies against platelet glyco-
proteins also bind to megakaryocytes, interfere with their 
maturation and lead to apoptosis with reduced platelet 
shedding. More recently, it has been shown that mega-
karyocytes can be destroyed also by CD8 cytotoxic T cells. 
Besides the level of thrombopoietin (TPO), the primary 
growth factor for the regulation of platelet production, in 
ITP is relatively low compared to patients with thrombo-
cytopenia’s resulting from megakaryocytic hypoplasia. 
This can be explained first by the fact that TPO pro duction 
is suboptimal as the Ashwell-Morell receptors in hepa-
tocytes are not triggered enough by the absence of old, 
 desialyated platelets and second by the exaggerated 
 removal of TPO bound to platelets. This means that the 
primary underlying mechanism may vary from patient to 
patient explaining why response to treatment also differs 
between patients. 
CLINICAL PRESENTATION19
Many patients remain asymptomatic with the diagnosis 
of ITP made only after a routine blood test. Others may 
have bleeding symptoms ranging from skin bleeding 
 (petechiae, purpura, bruises) (dry purpura) to mucosal 
bleeding (gingival bleeding, mouth blisters, epistaxis, 
blood in stool or urine, heavy menstrual bleeding) or 
 intracranial bleeding (wet purpura) appearing sponta-
neously or after trauma. Bleeding symptoms have mostly 
been reported in patients with a platelet count of less than 
30 x 109/L while life-threatening bleedings are rare in 
 patients with platelets higher than 10 x 109/L. Other fac-
tors influencing the bleeding risk are age, comorbidities, 
lifestyle, need for invasive procedures, need of treatment 
with anticoagulant or antiplatelet agents, etc.
CONSEQUENCES OF ITP DIAGNOSIS
The diagnosis and treatment of ITP have a major impact 
on the daily activities and a major negative impact on 
quality of life. Questionnaires have shown that the quality 
of life was at least as worse as patients with diabetes.20 The 
more recent ITP world impact survey showed that symp-
toms as fatigue and anxiety were reported with a high 
 severity in a high number of patients not only at diagnosis 
but also at follow-up.21 The disease has also a major impact 
on the healthcare (treatment costs) and socio-economic 
(family, employment) system.22
DIAGNOSTIC WORK UP1,3,23,24 
BASIC EVALUATION
•  Personal history (prescription and non-prescription drugs, 
consumption of beverages (tonic water, bitter lemon), 
food (tahini & sesame seeds, lupus beans), Jui herbal 
(Chinese) tea, herbal products, etc. (http://www.ouhsc.edu/ 
platelets/ditp.html); alcohol abuse, recent transfusions, etc.)
•  Familial history (to exclude inherited thrombocytope-
nias as Von Willebrand disease type 2B (VWD type 2 B), 
MYH9 associated syndromes, etc.)
•  Physical examination (with attention to node-bearing 
areas, size of liver and spleen)
•  A complete blood count with peripheral blood smear 
 examination (platelet count measured not only on EDTA 
but also heparin and citrate anticoagulated blood) (to 
exclude platelet aggregates (pseudo-thrombocytopenia), 
platelet aberrations (giant platelets, etc.), red cell abnormal-
ities (fragmentocytes, agglutination, microspherocytes, 
nucleated progenitors, etc.) and white cell abnormalities 
(neutrophilia, inclusions, progenitors, dysplastic changes, 
lymphocytosis, atypical lymphocytes, etc.) 
• Immuno globulin levels (to exclude CVID)
•  Direct antiglobulin test (positive in 20% of ITP) and reti-
culocytes (exclude Evan’s syndrome) 
• Virology: HIV, hep C, hep B 
•  H. pylori (antigen in stool or urea breath test) (in patients 
with digestive symptoms and/or living in geographical 
areas with high prevalence)
• Blood group (for transfusion policy)
•  Bone marrow aspirate and biopsy (with immunopheno-
typing, karyotyping, NGS panels for myelodysplasia, 
inherited thrombocytopenia and bone marrow failure 
syndrome) (only in selected patients with aberrant phys-
ical examination or blood smear abnormalities or refrac-
tory to treatment)
TESTS OF POTENTIAL UTILITY
•  Coagulation tests (basic ± additional tests) (to exclude 
DIC, VWD type 2B, thrombotic microangiopathy if sus-
pected signs or symptoms)
•  Antinuclear antibodies (positive in ±33% of ITP)
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•  Antiphospholipid antibodies (anti-cardiolipin, anti- beta 
2 glycoprotein I, lupus anticoagulant) (positive in 20-40% 
of ITP) (to exclude APS if history of arterial/venous 
throm bosis or foetal loss))
•  Thyroid function with antithyroid antibodies (to exclude 
thyroid dysfunction)
•  Pregnancy test in women of childbearing potential (to 
exclude gestational thrombocytopenia) 
•  Anti-platelet anti bodies (high degree of variability in the 
diagnostic test characteristics (sensitivity and specificity) 
of the available assays)
•  Virology: PCR for Cytomegalovirus, Epstein-Barr virus, 
parvovirus B19
•  Imaging: chest radiograph, abdominal ultrasound, CT-
scans or PET-scan (to exclude chest, abdominal organ 
pathology, such as portal hypertension and splenomegaly)
TESTS OF UNPROVEN UTILITY
Serum complement (optimal assay(s) to be confirmed), 
 serum TPO, immature platelet fraction
INDICATIONS FOR INITIATION OF 
 TREATMENT1,25
•  Treatment is mandatory in patients with “active bleeding” 
OR “platelets <10 x 109/L”. 
•  Treatment is generally recommended in patients with 
“No or mild bleeding” AND “platelets 10-30 x 109/L”. 
Observation is a potential option in selected patients 
 after evaluation of patient characteristics (age, comor-
bidities, previous bleeding history, preference, lifestyle, 
work, pregnancy, etc.)
•  No need for treatment unless special circumstances 
(previous bleeding history, lifestyle, work, invasive proce-
dures, concomitant anticoagulant or antiplatelet agents, 
etc.) in patients with “No bleeding” AND “platelets >30 x 
109/L”.
TREATMENT
The main treatment goal in all ITP patients must be to 
maintain a safe platelet count to prevent or stop bleeding 
and not to normalise the platelet count, to decrease activity 
restrictions and improve quality of life with a minimum of 
exposure to potentially toxic therapy.25 In the past we have 
seen that morbidity and mortality in ITP was related as 
much to infection as to bleeding.26
Before initiating treatment, consideration must be given to:
•  patient related factors such as age, performance status, 
comorbidities, lifestyle (sedentary vs. active) 
•  disease related factors such as platelet count and previous 
major bleeding
•  additional risk factors for bleeding such as the use of 
antiplatelet agents and anticoagulation, uraemia, poorly 
controlled hypertension, aneurysm, fever, chronic liver 
disease, history of peptic ulcer, etc.
•  treatment related factors such as expected response, 
contraindications to and expected side-effects 
•  the need of invasive procedures (Table 1)
•  easy access to care facilities
•  and not at least patient preferences or wishes
WHEN IS HOSPITALISATION OF ITP JUSTIFIED?
The 2019 updated International Consensus report advise 
to admit patients with active bleeding or medical condi-
tions which predict a higher bleeding risk or if platelets 
are ≤20 x 109/L.23 The recent ASH guidelines give only a 
conditional recommendation for admission to the hospital 
rather than treatment as an outpatient in newly diagnosed 
patients with platelets ≤20 x 109/L and no or mild muco-
cutaneous bleeding.27 In daily clinical practice, the decision 
to hospitalise a patient with ITP is based not only on 
platelet count but on the presence of bleeding symptoms 
and on factors influencing the bleeding risk as age, comor-
bidities, need of treatment with anticoagulant or antiplate-
let agents, uncertainty of diagnosis, newly diagnosed vs. 
chronic disease, refractoriness of the disease, easy access 
to care facilities, social concerns, etc.
TREATMENT OF NEWLY DIAGNOSED ITP 
(Figures 1 & 2)23,24,27
Newly diagnosed ITP patients are managed with cortico-
steroids with or without intravenous immunoglobulins 
(IgIV) depending on the severity of thrombocytopenia 
and/or of the bleeding signs and symptoms. Although 
 impressive responses are seen using these agents, the 
 responses are usually short lived. Thus, in adults, ITP is 
very frequently characterised by relapse upon tapering or 
discontinuation of treatment (only 30 to 50% of sustained 
response after discontinuation of corticosteroids).9,28-30
 Today, prolonged exposure to corticosteroids is no longer 
recommended because of long-term adverse events. The 
recent 2019 updated International Consensus report and 
2019 ASH ITP guidelines strongly recommend a short 
course of prednisone (or equivalent) (six to eight weeks 
treatment, tapering included) rather than prolonged treat-
ment. The aim is to stop corticosteroids in a short period 
of time, not to increase the dose when platelets are drop-
ping again and also to avoid a low dose chronically. In a 
meta-analysis of randomised controlled trials (RCTs) com-
paring pulses of high-dose dexamethasone vs. prolonged 




(day 14) and higher response rates were seen for dexa-
methasone but sustained response (six months) was not 
different. Changes in facial and body features were more 
important with prednisone or equivalents as neuropsychi-
atric side effects were more frequent with dexamethasone.31 
Therefore, both updated ITP guidelines suggest either 
dexamethasone or prednisone (or equivalent) as the type of 
corticosteroid for initial treatment. In Belgium prednisone 
is not available, prednisolone and methylprednisolone have 
to be used. Characteristics of treatment with corticosteroids 
and IgIV are shown in Table 2 and 3.
Platelet transfusions are “only” exceptionally indicated 
in case of life-threatening bleeding together with the 
 administration of corticosteroids and IgIV. Platelet trans-
fusions are frequently needed in this situation. Only in 
patients with life-threatening bleeding not responding to 
TABLE 3. Characteristics of treatment with intravenous immunoglobulins (IgIV).
Recommended dose: 400 mg/kg/d for 5 days or 1 g/kg/d for 1 or 2 days  
Short term response: ± 80%, rapid response
Durable response: exceptional, relapse between 14-28d
Repeated infusions possible
Mode of action: impairs clearance of antibody loaded platelets by macrophages by saturating the FcγRs on 
 macrophages, promoting the expression of inhibitory FcγRIIb, saturation of the FcRn which increases the clearance  
of autoreactive antibody, modulation of T and B cells (impairment of B cell function, increase of T suppressors)
Side effects: infusion related effects (can be managed with concomitant steroid premedication), headache, aseptic 
 meningitis, renal impairment (only for preparations containing sucrose), thromboembolic events
Subcutaneous (sc) Ig does not appear to be an alternative to IgIV
Expensive
































the previous mentioned measures to achieve haemostasis, 
rituximab and/or TPO-receptor agonists (TPO-RAs) can 
be added. 
TREATMENT OF PERSISTENT ITP 
(LASTING 3­12 MONTHS AFTER DIAGNOSIS) 
AND CHRONIC ITP (LASTING >12 MONTHS 
AFTER DIAGNOSIS) (Figure 1 & 2)23,24,27
Indications for starting treatment in persistent and chronic 
ITP are identical to those of newly diagnosed ITP. Relapse 
after a long treatment-free interval can be managed by 
 restarting first line treatment being steroids and/or IgIV 
if the patient was responsive before. As for newly diag-
nosed patients, again, a long-term steroid treatment or a 
low dose of steroids chronically must be avoided.
A subsequent therapy is indicated for those patients un-
responsive to, relapsing during or shortly after tapering 
of steroids. The most robust data are available for splenec-
tomy as surgical therapy and the TPO-RAs and rituximab 
as medical therapies (Table 4).
SPLENECTOMY
For decades, splenectomy has been the standard manage-
ment for ITP patients with persistent low platelets and a 
high bleeding risk, unresponsive or intolerant to corti-
costeroids. Historical data has shown that two-thirds of 
 patients could, attain a durable remission. Morbidity and 
mortality of laparoscopic splenectomy are low in the hands 
of experienced surgeons. The incidence of overwhelming 
sepsis is reduced with recommended vaccination protocols 
and antibiotics initiated at first sign of a systemic febrile 
illness. However, the last decades, physicians and patients 
frequently opt to postpone the removal of this healthy 
 organ.  As spontaneous remission of ITP up to twelve 
months after diagnosis can occur in ± 30 à 50% adults, an 
attempt should be made to delay splenectomy until after 
this point. Ideally, when possible, platelet count should be 
above 50 x 109/L before surgery to reduce complications as 
mentioned by the 2019 updated International consensus 
report. Above the age of 60, higher rates of relapses and 
more postoperative complications are seen with splenec-
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TABLE 4. Treatment options for relapsing and refractory adult ITP.
Retreatment options
•  Corticosteroids: 1 mg/kg/d orally (prednisone or equivalent), 40 mg/d x4/q14-28d, x1-3 orally (dexamethasone)
•  Immunoglobulins: 400 mg/kg/d x 5d or 1g/kg/d x 1-2d IV
Second- or further line treatment options
•  Splenectomy
•  TPO-RAs 
-> Romiplostim: 1-10 μg/kg/w sc  
-> Eltrombopag:  25-75 mg/d orally  
->  Avatrombopag: 20 to 40 mg/d orally to a minimum of 20 mg/week (not available in Belgium at publication)
•  Rituximab: 375 mg/m²/w for 4 weeks IV or 1000mg d1 and d15 IV
•  Other options: 
Dose Toxicities
Azathioprine 1-2 mg/kg/d orally Neutropenia, transaminase elevation, pancreatitis, etc.
Cyclophosphamide 1-2 mg/kg/d orally Nausea, vomiting, sterility, secondary AML, etc.
Cyclosporine 4-5 mg/kg/d orally Renal insufficiency, hypertension, neuropathy,  hypertrichosis, 
tremor, gingival hyperplasia, etc.
Danazol 400-800 mg/d orally Weight gain, hair loss, liver dysfunction, myalgia,  amenorrhea, etc.
Dapsone 75-100 mg/d orally  
(not after splenectomy)
Abdominal distension, anorexia, nausea, rash,  
haemolytic anaemia if G6PD deficiency, etc.
Mycophenolate mofetil 1000 mg 2x/d orally Headache, anorexia, nausea, abdominal distention, etc.
Vincristine
Vinblastine
1-2 mg IV/w, ≤ 6 w 
5-10 mg IV/w, ≤ 6 w
Neuropathy, constipation, hair loss, etc.
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tomy compared to ITP patients under the age of 60.32 
Characteristics of splenectomy with relative contraindica-
tions are shown in Table 5 and 6. 
RITUXIMAB
Rituximab has been used for treating relapsing and refrac-
tory ITP patients for almost twenty years. As RCTs are not 
available to establish optimal dose, schedule and timing of 
rituximab administration and to confirm efficacy and 
long-term safety, rituximab has still no license for treating 
ITP.33 The recently published French prospective ITP-ritux 
registry (n=248, persistent and chronic ITP) confirmed data 
from previously published cohorts and systemic reviews.34,35 
An overall (ORR) and complete response rate (CR) of ap-
proximately 61% and 32% has been shown. At 60 months 
of follow-up, 29.4% had a sustained response defined as 
a platelet count of >30 x 109/L without any additional treat-
 ment and without any bleeding. The only predictor of sus-
tained response seemed to be previous response to steroids. 
This registry focused on long-term safety. The  incidence of 
TABLE 5. Characteristics of splenectomy in adult ITP.
As at least 30-50% of patients remit in the first year after diagnosis, it is recommended to postpone splenectomy till the 
chronic ITP stage
Most effective durable treatment for adults (± 66% long-term normal platelets, ± 14% no response, ± 20% late failures)
Perioperative complications (comparable to other minor surgical procedures and general anaesthesia)
• Mortality: 1% for laparotomy, 0.2% for laparoscopy
• Morbidity: 13% for laparotomy, 10% for laparoscopy 
•  Acute venous thromboembolism: low but increased incidence (appropriate thrombosis prophylaxis postoperative 
especially when risk factors for thrombosis present, ASA if platelets >500 x 109/L)
•  Acute portal vein thrombosis: can occur in the first 3 months; range from asymptomatic to fatal; higher after 
 laparoscopy; start diagnostic investigations in patients with cramping abdominal pain, depressed bowel sounds and 
generalized bowel tenderness
Laparoscopic splenectomy: less postoperative pain, less infectious complications, earlier diet tolerance, shorter hospital 
stay but more haemorrhagic complications
No preoperative characteristic can predict success of splenectomy (111In platelet survival: if only splenic sequestration, 
90% response; less response if platelets very low, >3 previous treatments, elderly)
Postoperative thrombophylaxis should be considered as long as platelets are >30-50 x 109/L [21]  
Long-term effects:
•  Overwhelming post-splenectomy infection (S. pneumoniae, H. influenzae, N. meningitidis, E. coli, Capnocytophagia 
canimorsus, group B streptococcus, Ehrlichia and plasmodium species (cavé travellers!)) 
-> Appropriate and timely immunization (2-4w before or otherwise 2w after splenectomy)51 
-> Influenza vaccine: lifelong, once yearly  
-> Pneumococcal vaccine: one dose PCV13 followed, at least 2 months later, by one dose PPSV23, repeat PPSV23 
every 5 years. 
-> Meningococcal vaccine: one dose quadrivalent conjugated meningococcal vaccine (A, C, W, Y) and two doses 
meningococcal B vaccine, at least one month apart 
-> H influenzae vaccine: one dose if not previously vaccinated
• Prophylactic antibiotics in adults only when timely immunization not possible
• Education of each patient regarding risk of overwhelming infection life long
• Prompt treatment of infection life long





severe infections was less than 10%. Pre dominantly older 
patients with contributing factors were affected and 1/3 of 
the infections occurred in the first year after treatment. 
Opportunistic infections appeared exceptional with no case 
of progressive multifocal leuko ence phalopathy. Profound 
late-onset neutropenia was observed in <1% of patients. 
The registry showed that hypogammaglobulinemia could 
occur even several years after rituximab and need to be 
monitored.  No excess of secondary malignancies, venous 
thrombosis or cardiovascular events was noticed. Only 
5% of patients developed another autoimmune disease. 
No difference in short and long-term  responses between 
the lymphoma rituximab regimen (four intravenous in-
fusions at 375mg/m2 weekly) or the rheumatoid arthritis 
regimen (two fixed 1g rituximab  infusions two weeks apart) 
was observed. Retreatment with rituximab in responding 
patients was feasible with 92% of patients responding again 
with at least the same response (CR or partial response 
(PR)). Responses seemed comparable for splenectomised 
and non-splenectomised patients.35 
THROMBOPOIETIC AGENTS
The efficacy data of second-generation thrombopoietic 
agents (TPO-RAs as romiplostim, eltrombopag and ava-
trombopag) have confirmed the hypothesis that stimu-
lating platelet production is a valid treatment approach in 
ITP.36-39 TPO-RAs have been associated with more durable 
platelet responses and less treatment failure compared to 
placebo or standard of care in adult chronic ITP patients 
(defined in the pivotal trials as ITP lasting >6 months) 
 regardless of splenectomy status. Efficacy data are also 
identical for patients treated with the TPO-RAs in the 
acute or persistent ITP phase.40-42 The response rates ob-
tained in the pivotal studies were reproduced in open- 
label studies and real-life enrolling patients with more 
 severe comorbidities and older age. Patients relapsing after 
or refractory to rituximab seem to be as responsive as 
 cohorts were previous exposure to rituximab was less. 
Treatment with TPO-RAs result in a reduction of bleeding 
events, in less use of rescue medication or splenectomy 
and permit the majority of patients receiving concurrent 
ITP drugs to reduce or discontinue these therapies and 
avoid further immunosuppression. An additional role of 
the TPO-RAs may be to use the drug intermittently around 
the time of an anticipated bleeding risk. TPO-RAs are very 
well tolerated. As the experience with TPO-RAs in the 
clinic is exceeding twelve years, we suppose that possible 
risks of long-term use of TPO-RAs are almost known.37,38 
Characteristics of treatment with TPO-RAs and risks of 
long-term treatment are shown in Tables 7 and 8. Inter-
national guidelines, as well as the regulatory authorities 
worldwide recommended, suggested and reimbursed romi-
plostim and eltrombopag as a second or third-line treat-
ment option since 2009.3,43  Today, in Belgium, the TPO-
RAs, romiplostim and eltrombopag, are reimbursed for the 
treatment of chronic ITP (ITP lasting >12 months) refrac-
tory or intolerant to corticosteroids after splenectomy or 
when surgery is contraindicated. We are waiting for the 
extended reimbursements of romiplostim and eltrombo-
pag for persistent ITP once European Medicines Agency 
labels will have been adjusted. Despite the initial assump-
tion that TPO-RAs would be a life-long therapy, practical 
experience has shown that a significant number of patients 
do stop treatment (no efficacy, adverse events, ITP or non-
ITP related death or spontaneous remission). Spontaneous 
remission or TFR is defined as a treatment-free period of 
≥6 months with platelets >50 x 109/L and no need of ITP 
rescue medication. The Belgian Hematology Society (BHS) 
survey from 2018 showed that TFR was seen in about 
22% of ITP patients treated with TPO-RAs in daily clini-
cal practice in Belgium. TFR was seen not only in acute 
or persistent but also in chronic ITP and seemed inde-
pendent of splenectomy and number of treatments given 
before.44  In the future the incidence of TFR is thought to 
be even higher when the use of a forced tapering schedule 
will become common practice.
PRACTICE GUIDELINES
TABLE 6. Relative contraindications for splenectomy.
Platelet count <20 x 109/L before surgery (platelets  
>50 x109/L are ideal to limit the risk of postoperative 
bleeding, to minimize trauma to upper airway  
during general anaesthesia)
Older age (>60 years, higher rates of relapse and more 
postoperative complications)
Comorbidities increasing perioperative risk
• Diabetes Mellitus
• Heart failure, ischemic heart disease, 
• Arrythmias, valvular disease
• Uncontrolled arterial hypertension
• Chronic obstructive pulmonary disease, asthma
• Renal insufficiency (Cr >2mg/dl)
• History of stroke
• Severe obesity
Low functional capacity
Refusal by the patient
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TABLE 7. Characteristics of treatment with TPO-receptor agonists (RAs).
Dosing of TPO-RAs 
• Romiplostim 
->  start with 1μg/kg sc
->  Increase dose with 1μg/kg/w if platelet count <50 x 109/L till a maximum dose of 10μg/kg 
-> Maintain dose if platelet count between 50-150 x 109/L
-> Reduce dose with 1μg/kg if platelet counts between 150-250 x 109/L for 2 weeks
->  Stop dosing and reassess after 1 week if platelet count >250 x 109/L and restart dosing with -1μg/kg if platelet count  
<150 x 109/L 
-> If platelet count ≥50 x 109/L for at least 4 weeks without dose adjustment, assess platelet count once monthly 
-> Consider self-administration or home administration by a nurse or caregiver
• Eltrombopag 
-> Not eat calcium, iron, magnesium, aluminium rich food 4h before and 2h after ingestion 
-> Start with 50mg orally once daily (25mg in patients from East Asia and those with a Child-Pugh ≥5)
-> If platelet count <50 x 109/L after 2 weeks, increase dose to 75mg once daily 
-> If platelet count between 50-150 x 109/L, maintain dose
-> If platelet count between 150-250 x 109/L, reduce to 25mg once daily
->  If platelet count >250 x 109/L, stop dosing, monitor platelet count twice weekly and reinitiate at a daily dose  reduced by  
25 mg if platelet count <100 x 109/l
-> If platelet count ≥ 50 x 109/L for at least 4 weeks without dose adjustment, assess platelet count once monthly
• Avatrombopag (not available in Belgium)
-> No dietary limitations 
-> Start with 20mg orally once daily with food
-> Asses platelet weekly and titrate to a platelet count between 50-200 x 109/L
-> Maximum dose 40 mg once daily orally
-> Minimum dose 20 mg once weekly
Romiplostim binds the extracellular TPO-R domain identical to endogenous TPO; eltrombopag and avatrombopag  
bind the transmembrane TPO-R domain 
TPO-RAs induce durable platelet responses (60% stable responses, 25% variable responses, 15% minor or no 
 response) and less treatment failures 
• regardless of splenectomy status 
• regardless of response to rituximab 
• in chronic (>6 months) ITP but also in persistent and newly diagnosed patients   
TPO-RAs reduce the need of rescue medication (IgIV, splenectomy) and permit to reduce or discontinue concurrent  
ITP drugs (corticosteroids, etc.) and avoid further immunosuppression 
TPO-RAs reduce bleeding events 
TPO-RAs improve health-related quality of life
TPO-RAs are very well tolerated (mild to moderate headache is most common adverse event), 
( ± 10-15% discontinuation because of intolerance)
Continuous treatment (romiplostim once weekly sc, eltrombobag and avatrombopag once daily orally)
The risk-benefit balance in a patient with a thrombo-embolic risk should be considered before starting TPO-RA  
(use with caution in patients with APS and previous thrombotic events) 
Switching TPO-RAs: can help patients with poor responses, with large fluctuations, side effects and with route of 
 administration problems 
Treatment free remission: 10-30% of patients (defined as >50 x 109/L lasting as least 6 months after discontinuation  
of the TPO-RAs) 
No consensus on tapering 
• Consider tapering in those with a complete response on a low dose and stable platelet count for >6 months
• An acceptable tapering scheme could be:
->  Romiplostim: reduce dose x-1 μ/kg each two weeks
->  Eltrombopag: reduce dose with 25mg each 2 weeks to 25mg each 4 days before interrupting





Medical therapies with less robust data for subsequent 
treatment are azathioprine, cyclophosphamide, cyclo-
sporin A, danazol, dapsone, mycophenolate mofetil and 
 vincristine/vinblastine. These agents have been used after 
treatment failure in both splenectomised and non-sple-
nectomised patients for decades. These treatment options 
are characterised by variable individual responses after 
days, weeks to months and significant long-term side 
 effects such as immune suppression and many others, 
which must be considered by patient and physician. Most 
of the retrospective data according these agents show only 
a response rate of 20-50% with lower response rates in more 
heavily treated patients and with longer disease duration.1,45  
Some characteristics of these agents are shown in Table 4. 
We presume that most of these agents work by immuno-
suppression or immunomodulation. Vincristine/vinblastine 
seem to inhibit the phagocytosis of antibody-loaded plate-
lets by macrophages. For dapsone, it has been postulated 
that the splenic macrophages are redirected to phagocyto-
sis of the haemolytic red blood cells with reduction of the 
platelet phagocytosis.
NOVEL AGENTS
Due to better understanding of the pathophysiology, novel 
therapies targeting other pathways are explored. Fostama-
tinib, the first spleen tyrosine kinase (Syk) inhibitor ob-
tained already Food and Drug Administration approval 
for ITP patients with an insufficient response to previous 
treatment. Syk inhibition will reduce antibody-mediated 
platelet destruction and regulates autoantibody produc-
tion.46  The same mode of action is expected for new Bruton 
PRACTICE GUIDELINES
TABLE 8. Possible risks of long-term use of TPO-receptor agonists (RAs).
Loss of efficacy with prolonged stimulation of megakaryopoiesis
Bone marrow fibrosis
• Follow up of blood cell count and smear regularly
• If loss of response, new cytopenia or new morphologic abnormalities, a bone marrow biopsy should be done
• Discontinue TPO-RA in case of reticulin fibrosis grade 3 or collagen fibrosis
• Continue TPO-RA in case of reticulin fibrosis grade 2 and rebiopsy 6 months later [37]  
Thrombosis 
• ITP is a procoagulant condition (more arterial thrombosis (AT) and venous thromboembolism (VTE))
• TPO-RAs increase the risk of VTE and AT compared to ITP
• Thrombosis not correlated with type, duration, dose of TPO-RA or platelet count
• Splenectomy increases the risk of VTE.
• TPO-RAs do not increase the thrombotic risk in splenectomised patients
• Careful consideration benefits vs. risk of thromboembolism 
Rebound thrombocytopenia: more severe thrombocytopenia after drug discontinuation (10%) due to endogenous  
TPO deprivation (advised to taper TPO-RAs and not to withdraw them abruptly)
Fluctuating platelet counts: more frequent with romiplostim
Neutralizing antibody formation to romiplostim (not existing for small molecules): incidence of ± 6/1000, no cross- 
reaction with endogenous TPO
• If loss of response: test for the formation of anti-romiplostim antibodies 
Hepatotoxicity: 10% of patients on eltrombopag develop elevated liver enzymes which occurs more frequently in the first year
• Control of liver function before and each 2 weeks during titration and monthly following achievement of a stable dose
Cataract
•  Recommended to do an ophthalmologic examination in patients with one or more risk factors  
(older age, steroid use, smoking) and treated with eltrombopag or romiplostim
Induction of malignancy: no indication that the TPO-RAs induce hematological and non-hematological malignancies in ITP
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tyrosine kinase inhibitors as rilzabrutinib.47  Phase II trial 
data with roxanolixizumab, a humanised anti-FcRn mono-
clonal antibody and efgartigimod, a human IgG Fc-frag-
ment blocking the binding of IgG to FcRn confirmed that 
 blocking FcRn is a novel therapeutic approach in ITP 
by increasing the clearance of antiplatelet antibodies.48,49 
Reduction of antibody formation could also be the goal of 
treatment with anti-CD38, anti-CD40 ligand antibodies 
and immunoproteasome inhibition. Sialylated IgG and 
stra domers are tested to reduce platelet phagocytosis. Com-
plement inhibitors could reduce complement mediated 
platelet lysis.7,15,45,50 
THE BHS RECOMMENDS THE FOLLOWING 
SUBSEQUENT TREATMENT OPTIONS FOR  
ITP PATIENTS WHO ARE  INTOLERANT  
OR UNRESPONSIVE TO OR RELAPSE AFTER 
INITIAL CORTICOSTEROID TREATMENT AND 
HAVE A RISK OF BLEEDING  
(PLATELETS <30 X 109/L OR BLEEDING 
SYMPTOMS):  
•  TPO-RAs must be available irrespective of the duration 
of ITP and the splenectomy status. TPO-RAs are the 
best treatment option for patients who prefer a durable 
platelet response while avoiding surgery and who have 
an acceptable thrombotic risk. 
•  Rituximab can be used irrespective of the duration of 
ITP and the splenectomy status. Rituximab is a good 
treatment option in patients who want to avoid long-
term treatment, surgery and who have an acceptable in-
fectious risk. 
•  Splenectomy is only indicated in patients with a severe 
bleeding tendency but should be delayed (if possible) to 
at least twelve months after diagnosis as spontaneous 
 remission can occur in this time period. The best res-
ponses and the lowest complication rates are seen in 
 patients <60 years. Splenectomy is the best treatment 
option for patients who prefer a durable platelet response 
while avoiding long-term medications.
•  Other medical therapies as azathioprine, cyclophospha-
mide, cyclosporin A, danazol, dapsone, mycophenolate 
mofetil and vincristine/vinblastine have to be considered 




Thrombocytopenia develops in 5-10% of women during 
pregnancy or in the immediate postpartum period. ITP is 
an uncommon but important cause of thrombocytopenia 
TABLE 9. Thrombocytopenia in pregnancy.
ITP: 
•  diagnosis of exclusion (exclude secondary ITP 
 especially SLE and APS)
•  more likely if a history of thrombocytopenia before 
pregnancy 
• may present at any point during pregnancy 
Gestational thrombocytopenia: 
• platelets mostly >70 x 109/L
• develops in the late second and third trimester
•  not associated with an increase in maternal or foetal 
complications
Preeclampsia: 
•  arterial hypertension (systolic >140 and/or diastolic 
blood pressure >90mm Hg), proteinuria (>300 mg/24h) 
and thrombocytopenia in 50% of patients
• thrombocytopenia may precede other signs
• develops after 20 weeks of gestation  
• delivery of the foetus after stabilisation of the mother 
•  platelet transfusions in the setting of severe 
 thrombocytopenia and bleeding
HELLP syndrome: 
•  Nausea, malaise, upper right quadrant pain or 
 epigastric pain, microangiopathic haemolytic anaemia, 
abnormal liver function (transaminases >70U/L) and 
thrombocytopenia 
• most frequent in third trimester
• delivery of the foetus after stabilisation of the mother
•  platelet transfusions in the setting of severe 
 thrombocytopenia and bleeding 
Thrombotic trombocytopenic purpura (TTP) and 
 haemolytic uremic syndrome (HUS):
•  non-immune microangiopathic haemolytic anaemia, 
thrombocytopenia, and organ impairment (neurological 
changes more pronounced in TTP and renal changes 
in HUS)
• TTP most frequent in the second trimester
• 90% of HUS developing in the postpartum period
•  Sometimes difficult to distinguish from hypertensive 
disorders and HELLP syndrome
•  plasma exchange and replacement with fresh frozen 
plasma 
Acute fatty liver of pregnancy: 
•  malaise, anorexia, nausea, vomiting, epigastric or 
right upper quadrant pain, mental status changes and 
cholestatic liver abnormalities with DIC 
• typically occurs in primipara in the third trimester
• delivery of the foetus after stabilisation of the mother
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in pregnancy (3% of all cases of the thrombocytopenia). 
The incidence of ITP ranges from 1-2 per 1,000 pregnancies 
to 1 per 10,000 for severe cases. 
DIAGNOSTIC WORK­UP
Diagnosis and work-up are similar to non-pregnant women 
but differential diagnosis includes pregnancy-specific con-
ditions such as gestational thrombocytopenia, coagulo-
pathy and hypertensive, microangiopathic or hepatic dis-
orders. Those are detailed in Table 9 and must be separated 
from ITP because their successful management differs 
completely from that of ITP. 
FOLLOW­UP AND TREATMENT (Figure 3)
Pregnant women with ITP require careful monitoring 
(monthly until week 28, every two weeks until week 36, 
weekly until delivery). The indications for treatment of 
the pregnant woman do not differ from those of a non- 
pregnant person. However, a platelet count of 50 x 109/L 
is preferred for vaginal delivery and caesarean section and 
a platelet count of ≥70 x 109/L is recommended for epi-
dural anaesthesia. If treatment is necessary, prednisone or 
equivalent (preferred to pulse dexamethasone, which also 
crosses the placenta) 1mg/kg/day (pre-pregnancy weight) 
should be considered as first-line and gradually titrated to 
the lowest effective dose. High doses steroids should be 
avoided in first trimester to prevent congenital anomalies 
such as cleft palate and prolonged high doses because of 
exaggerated toxicity during pregnancy (gestational diabetes, 
hypertension, osteoporosis, weight gain and psychosis). 
IgIV (1g/kg 1-2 days) are also considered as an appropriate 
first-line treatment for ITP during pregnancy as they may 
increase the platelet count faster than steroids. Patients 
who fail to respond to corticosteroids or IgIV alone may 
respond to the combination of these agents. Laparoscopic 
splenectomy can be safely performed in the second trimes-
ter. Splenectomy is not recommended in the first trimester 
due to the risk of induction of premature labour or in the 
third trimester due to bad visualisation of the surgical 
field. Azathioprine, cyclosporin A and rituximab are not 
known to be teratogenic. Rituximab has been used in 
pregnant women but can be associated with prolonged B 
cell depletion in neonates exposed in utero resulting in 
delaying the start of vaccination. The effects on pregnancy 
outcomes and on the foetus with TPO-RAs are unknown 
and their experience during pregnancy is anecdotal. This 
treatment should only be considered in late pregnancy if 
the potential benefit to the mother justifies the potential 
risk to the foetus. 
Care should be coordinated by experienced colleagues 
from haematology, obstetrics and neonatology. Maternal 
and neonatal outcomes are generally favourable but severe 
ITP carries a higher risk of maternal post-partum haemor-
rhage. Invasive deliveries (forceps or vacuum-assisted) 
should be avoided. Thromboprophylaxis and anticoagula-
tion should be managed according to standard protocols, 
as ITP does not prevent thrombosis. Although, the mini-
mal platelet count required in this setting still needs to be 
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validated by evidence-based guidelines. Tranexamic acid 
is a safe and effective adjunct in the peri-partum period. 
Nonsteroidal anti-inflammatory drugs should be avoided 
in the post-partum period if the platelet count is <70 x 
109/L.
FOLLOW­UP OF THE NEONATE
With respect to the neonates, platelet counts <20 x 109/L 
and <50 x 109/L are seen in respectively 1-5% and 10% 
and 5-15% will require therapy. Thrombocytopenia in 
 neonates is due to transplacental passage of antiplatelet 
antibodies present in mothers with ITP. This can also 
 occur with maternal ITP in remission with or without 
splenectomy. Neonatal intracranial haemorrhage is seen 
in <1% and is not associated with the mode of delivery. 
Therefore, the mode of delivery in pregnant ITP patients 
should be solely based on obstetrical considerations. How-
ever, invasive procedures during labour (scalp electrodes, 
vacuum extractor, and forceps) should be avoided, as they 
are associated with an increased haemorrhagic risk to the 
foetus. Cordocentesis and foetal scalp or percutaneous 
umbilical blood sampling should also be avoided. A cord 
platelet count is indicated after delivery and serial platelet 
counts should be obtained in the new-borns at birth and 
in the first week postpartum as the onset of thrombocyto-
penia can be delayed. IgIV and platelet transfusions are 
indicated to manage bleeding or if platelet count <30 x 109/L 
in the neonates. Cerebral imaging is recommended in new- 
borns with platelets <50 x 109/L to exclude an intracranial 
haemorrhage.
COUNSELLING OF WOMEN WITH ITP
•  ITP is usually not a contra-indication for pregnancy 
•  risk of foetal thrombocytopenia exist even in splenecto-
mised mothers  
•  no correlation between the platelet count of the mother 
and the new-born. 
•  the most reliable predictor of neonatal thrombocytope-
nia is a history of low platelet count at delivery in a prior 
sibling 
•  breastfeeding should not be discouraged.
SUPPORTIVE TREATMENT FOR ITP 
 PATIENTS
•  Antifibrinolytic agents
•  Oral iron supplements if required
•  Local application of adrenalin-soaked nose pads
•  Nasal cauterisation
•  Hormonal therapy to prevent menorrhagia
•  Control of blood pressure
•  Stop or avoid acetylsalicylacid (ASA), nonsteroidal anti- 
inflammatory drugs, antiplatelet agents, anticoagulation 
if appropriate
MANAGEMENT OF ITP DURING THE 
 COVID-19 PANDEMIC56 
In newly diagnosed patients, it seems advisable to avoid 
corticosteroids or to use the lowest effective dose as possible 
for the shortest time to not increase the susceptibility to 
the SARS-CoV-2. IgIV can be used at diagnosis or at relapse. 
The UK ITP experts even recommend TPO-RAs as first 
line treatment. Chronic ITP patients should continue their 
chronic treatment. As ITP, TPO-RAs and COVID-19 infec-
tion have all an increased thrombotic risk, ITP patients 
with a severe COVID-19 infection and treated with TPO-
RAs, must receive low molecular weight heparin (LMWH) 
if platelets >30 x 109/L or calf compression therapies if 
<30 x 109/L. Patients on high dose steroids for weeks, low 
dose steroids with another immunosuppressant, rituxi-
mab during the last twelve months with another immuno-
suppressant or corticosteroids, splenectomy with an im-
munosuppressant and/or concomitant comorbidities as 
age >70 years, diabetes mellitus, pre-existing lung, renal 
or cardiac disease and hypertension should strongly be 
advised to minimise the risk of SARS-CoV2 infection by 
social distancing, wearing protective masks and hygienic 
measures. Subsequent therapies as rituximab and sple-
nectomy should be postponed, if possible, due to the in-
creased infection risk. 
CONCLUSION
Primary ITP is characterised by an isolated low platelet 
count. The clinical picture (mild to severe bleeds) is as 
 heterogeneous as the pathophysiology of the disorder. 
 Today we know that ITP pathogenesis is associated with 
B and T cell defects, which lead to platelet and megakaryo-
cyte damage resulting in platelet destruction and ineffi-
cient thrombopoiesis. Although severe bleeds in adults are 
not much higher than 10%, the disease has a major impact 
on daily activities and quality of life.57 ITP patients also 
have a higher mortality rate than the general population. 
This is not only due to bleeding but also to infections and 
cardiovascular problems. Personalised treatment decisions 
remain a challenge in many cases since the underlying 
pathogenesis can differ between patients. The BHS recom-
mends TPO-RAs, rituximab and splenectomy as the sub-
sequent treatment options for ITP patients who are intole-
rant or unresponsive to or relapse after initial corti costeroid 
treatment and have a risk of bleeding (platelets <30 x 109/L 
OR bleeding symptoms). TPO-RAs and rituximab should 
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be used irrespective of the duration of ITP, while splenec-
tomy should be deferred for at least twelve months after 
diagnosis. Currently no pathophysiological difference is 
known for acute, persistent and chronic ITP. Today, we are 
waiting in Belgium for the extension of the reimbursement 
of TPO-RAs for patients with an ITP duration of less than 
twelve months. 
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